Related Experiment Videos
Vaccination of children following a previous hypotonic-hyporesponsive episode
1National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia.
Insights
Children who experienced hypotonic-hyporesponsive episodes (HHE) can safely continue standard pertussis vaccination schedules. Further vaccinations in specialized clinics showed no serious adverse events or recurrent HHE.
Area of Science:
- Pediatric immunology
- Vaccine safety research
- Public health
Background:
- Hypotonic-hyporesponsive episodes (HHE) were historically viewed as a contraindication for pertussis vaccination.
- This study addresses the safety concerns surrounding pertussis vaccination in children with a history of HHE.
Purpose of the Study:
- To evaluate the safety of continued pertussis vaccination in children with a history of HHE.
- To determine if further vaccinations lead to adverse events or recurrence of HHE.
Main Methods:
- Retrospective chart review of 66 children with a history of HHE, assessed in specialized pediatric clinics.
- Analysis of vaccination records, focusing on pertussis vaccine type (whole-cell or acellular) received prior to HHE and subsequent vaccinations.
Main Results:
- 64 of 66 children received further vaccinations, primarily with pertussis-containing vaccines (55 acellular, 4 whole-cell), without serious adverse events.
- No instances of HHE were reported following the further vaccinations in the specialized clinic setting.
Conclusions:
- Previously healthy children experiencing HHE reactions can safely adhere to standard vaccination schedules.
- Specialized assessment and vaccination clinics can provide a safe environment for children with a history of HHE to receive necessary immunizations.
Background:
Hypotonic-hyporesponsive episodes (HHE) were once considered a contraindication to pertussis vaccination.
Methodology:
To evaluate the safety of further vaccination, chart review was conducted of 66 children who had experienced an HHE, and who were assessed in one of three special clinics in three capital city tertiary paediatric hospitals. Immediately prior to the HHE, 63 children had received whole-cell pertussis vaccine, three had received acellular pertussis vaccine.
Results:
Sixty-four of the 66 children were vaccinated in the special clinic, 59 with pertussis-containing vaccines (55 acellular, four whole-cell), without serious adverse events. There were no HHE after these further vaccinations.
Conclusions:
Previously healthy children who experience HHE reactions can safely continue standard vaccination schedules.